← Human Trials & Peer-Reviewed Studies
Oxytocin levels in response to CRH administration in hypopituitarism and hypothalamic damage: a randomized, crossover, placebo-controlled trial
Plain-language guide to PMID 39824923 (2025): single-blind randomized controlled trial study of Oxytocin and ACTH (Corticotropin).
Key Facts
- PMID
- 39824923
- Journal
- Scientific reports
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Asla Q et al. (17 authors)
- DOI
- 10.1038/s41598-025-86566-y
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Oxytocin and ACTH (Corticotropin), published as a randomized controlled trial.
This study aimed to examine the effects of CRH on oxytocin release in HHD compared to healthy controls (HC) and to describe the psychopathology, sexual function and QoL and their associations with oxytocin.
Nineteen HHD patients (10 females) and 20 HC (11 females) completed two visits, receiving CRH or placebo in random order and completed validated questionnaires to assess psychopathology, sexual function and QoL.
Samples were collected over 120 min to assess oxytocin.
Why It Was Studied
Therefore, identifying a provocative test to diagnose an OXT-D will be important.
This is a single-blind, randomized, placebo-controlled, proof-of-concept study (NCT04902235) with crossover assignment (CRH vs. placebo).
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, single-blind, placebo-controlled and crossover.
The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.
Only one side, usually the participants, was kept unaware of whether Oxytocin was given.
Some participants received a placebo instead of Oxytocin, giving a reference point.
Each person switched between Oxytocin and the comparison at some point, usually with a gap in between.
What Was Measured
Therefore, identifying a provocative test to diagnose an OXT-D will be important.
PubMed files the paper under topics including Oxytocin, Corticotropin-Releasing Hormone, Hypopituitarism, Quality of Life, Hypothalamus and Hypothalamic Diseases.
The authors tagged it with the keywords Arginine-vasopressin deficiency, Hypothalamic damage and Pituitary disease.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Oxytocin and ACTH (Corticotropin).
The publication is from 2025 (Scientific reports), a journal based in England.
More context: the Oxytocin compound page and the ACTH (Corticotropin) compound page, all human trials.
Our Notes on the Compounds
Oxytocin: A peptide hormone with established obstetric medical uses and a less settled role in research on behavior, sexual function and appetite.
ACTH (Corticotropin): The 39-amino-acid pituitary hormone that drives cortisol production; given as repository corticotropin (Acthar Gel).
CRH (Corticotropin-Releasing Hormone): The 41-amino-acid hypothalamic hormone that triggers ACTH release; corticorelin is used diagnostically.
Related Pages
- Oxytocin in the library
- ACTH (Corticotropin) in the library
- CRH (Corticotropin-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.